Can Investigational Medication Reduce Eczema Symptoms in Children?

Trial Objective

The purpose of this study is to see if an investigational medication, dupilumab, can be used safely and effectively to reduce eczema symptoms in children age 6 to 11.

The safety and effectiveness of this investigational medication has not been evaluated by the U.S. Food and Drug Administration (FDA) for children.


This trial is active and currently recruiting.

How to Participate

For more information, call 303.398.1811 or complete the form below.

Who Can Participate

Children with moderate-to-severe atopic dermatitis (AD), also known as eczema.

Estimated Time Commitment

13 visits over seven months

Trial Location

National Jewish Main Campus, Denver, CO



Trial Sponsors

Regeneron Pharmaceuticals, Inc.




Any Gender

Principal Investigators

Request More Information